William J Sandborn (William Sandborn, W J Sandborn)

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 38

Top Topics

Ulcerative Colitis

Patients With Inflammatory Bowel Disease

Top Venues

Alimentary pharmacology & therapeutics

Science advances

Inflammatory bowel diseases

Crohn's & colitis 360

This page only lists publications with an associated author ORCID identifier.

Publications

Aaron T Mayer, Derek R Holman, Anav Sood, Utkarsh Tandon, Salil S Bhate, Sunil Bodapati, Graham L Barlow, John T Chang, Sarah Black, Erica C Crenshaw, Alexander N Koron, Sarah E Streett, Sanjiv Sam Gambhir, William J Sandborn, Brigid S Boland, Trevor J Hastie, Robert Tibshirani, John T Chang, Garry P Nolan, Christian M Schürch, Stephan R Rogalla
A tissue atlas of ulcerative colitis revealing evidence of sex-dependent differences in disease-driving inflammatory cell types and resistance to TNF inhibitor therapy. Science advances 9 (3) (2023)
Aaron T Mayer, Derek R Holman, Anav Sood, Utkarsh Tandon, Salil S Bhate, Sunil Bodapati, Graham L Barlow, John T Chang, Sarah Black, Erica C Crenshaw, Alexander N Koron, Sarah E Streett, Sanjiv Sam Gambhir, William J Sandborn, Brigid S Boland, Trevor J Hastie, Robert Tibshirani, John T Chang, Garry P Nolan, Christian M Schürch, Stephan R Rogalla
A tissue atlas of ulcerative colitis revealing evidence of sex-dependent differences in disease-driving inflammatory cell types and resistance to TNF inhibitor therapy. Science advances 9 (3) (2023)
Aaron T Mayer, Derek R Holman, Anav Sood, Utkarsh Tandon, Salil S Bhate, Sunil Bodapati, Graham L Barlow, John T Chang, Sarah Black, Erica C Crenshaw, Alexander N Koron, Sarah E Streett, Sanjiv Sam Gambhir, William J Sandborn, Brigid S Boland, Trevor J Hastie, Robert Tibshirani, John T Chang, Garry P Nolan, Christian M Schürch, Stephan R Rogalla
A tissue atlas of ulcerative colitis revealing evidence of sex-dependent differences in disease-driving inflammatory cell types and resistance to TNF inhibitor therapy. Science advances 9 (3) (2023)
Aaron T Mayer, Derek R Holman, Anav Sood, Utkarsh Tandon, Salil S Bhate, Sunil Bodapati, Graham L Barlow, John T Chang, Sarah Black, Erica C Crenshaw, Alexander N Koron, Sarah E Streett, Sanjiv Sam Gambhir, William J Sandborn, Brigid S Boland, Trevor J Hastie, Robert Tibshirani, John T Chang, Garry P Nolan, Christian M Schürch, Stephan R Rogalla
A tissue atlas of ulcerative colitis revealing evidence of sex-dependent differences in disease-driving inflammatory cell types and resistance to TNF inhibitor therapy. Science advances 9 (3) (2023)
William J Sandborn, Jingjing Chen, Krisztina Kisfalvi, Edward V Loftus, Geert D'Haens, Ninfa Candela, Karen Lasch, Douglas C Wolf, Sharif M Uddin, Silvio Danese
Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies. Crohn's & colitis 360 5 (3) (2023)
Gajanan D Katkar, Ibrahim M Sayed, Mahitha Shree Anandachar, Vanessa Castillo, Eleadah Vidales, Daniel Toobian, Fatima Usmani, Joseph R Sawires, Geoffray Leriche, Jerry Yang, William J Sandborn, Soumita Das, Debashis Sahoo, Pradipta Ghosh
Artificial intelligence-rationalized balanced PPARα/γ dual agonism resets dysregulated macrophage processes in inflammatory bowel disease. Communications biology 5 (1) (2022)
Niels Vande Casteele, William J Sandborn, Brian G Feagan, Séverine Vermeire, Parambir S Dulai, Andres Yarur, Xavier Roblin, Shomron Ben-Horin, Iris Dotan, Mark T Osterman, Maria Rosario, Teresa McRorie Osborn, Julian Panes, Dirk Lindner, Christian Agboton
Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study. Alimentary pharmacology & therapeutics 56 (3) (2022)
Silvio Danese, Barrett G Levesque, Brian G Feagan, Alina Jucov, B R Bhandari, Rish K Pai, Kristen Taylor Meadows, Brian J Kirby, Jean-Marie Bruey, Allan Olson, Robin Osterhout, Courtney Van Biene, Julia Ford, Richard Aranda, Kartik Raghupathi, William J Sandborn
Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' reply. Alimentary pharmacology & therapeutics 55 (6) (2022)
Silvio Danese, Barrett G Levesque, Brian G Feagan, Alina Jucov, Bal Raj Bhandari, Rish K Pai, Kristen Taylor Meadows, Brian J Kirby, Jean-Marie Bruey, Allan Olson, Robin Osterhout, Courtney Van Biene, Julia Ford, Richard Aranda, Kartik Raghupathi, William J Sandborn
Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis. Alimentary pharmacology & therapeutics 55 (4) (2022)
William J Sandborn, Alessandro Armuzzi, Giuseppina Liguori, Peter M Irving, Ala I Sharara, Rajiv Mundayat, Nervin Lawendy, John C Woolcott, Silvio Danese
Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis. Inflammatory bowel diseases 28 (9) (2022)
Rocio Sedano, Christopher Ma, Rish K Pai, Geert D' Haens, Leonardo Guizzetti, Lisa M Shackelton, Julie Remillard, Paolo Gionchetti, Ilyssa O Gordon, Stefan Holubar, Maia Kayal, Gregory Y Lauwers, Reetesh K Pai, Darrell S Pardi, Mark A Samaan, David F Schaeffer, Bo Shen, Mark S Silverberg, Brian G Feagan, William J Sandborn, Vipul Jairath
An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. Alimentary pharmacology & therapeutics 53 (10) (2021)
Sushrut Jangi, Hyuk Yoon, Parambir S Dulai, Mark Valasek, Brigid Boland, Vipul Jairath, Brian G Feagan, William J Sandborn, Siddharth Singh
Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis-authors' reply. Alimentary pharmacology & therapeutics 53 (8) (2021)
Chung Sang Tse, Siddharth Singh, William J Sandborn
A Framework for Clinical Trials of Neurobiological Interventions That Target the Gut-Brain Axis in Inflammatory Bowel Disease. Inflammatory bowel diseases (2021)
Ahmed Almradi, Christopher Ma, Geert R D'Haens, William J Sandborn, Claire E Parker, Leonardo Guizzetti, Paula Borralho Nunes, Gert De Hertogh, Roger M Feakins, Reena Khanna, Gregory Y Lauwers, Aart Mookhoek, Reetesh K Pai, Laurent Peyrin Biroulet, Robert Riddell, Christophe Rosty, David F Schaeffer, Mark A Valasek, Siddharth Singh, Eileen Crowley, Brian G Feagan, Vipul Jairath, Rish K Pai
An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. Alimentary pharmacology & therapeutics 53 (7) (2021)
Sushrut Jangi, Hyuk Yoon, Parambir S Dulai, Mark Valasek, Brigid S Boland, Vipul Jairath, Brian G Feagan, William J Sandborn, Siddharth Singh
Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. Alimentary pharmacology & therapeutics 52 (6) (2020)
Matthew Bohm, Ronghui Xu, Yiran Zhang, Sashidhar Varma, Monika Fischer, Gursimran Kochhar, Brigid Boland, Siddharth Singh, Robert P Hirten, Ryan C Ungaro, Eugenia Shmidt, Karen Lasch, Vipul Jairaith, David Hudesman, Shannon Chang, Dana Lukin, Arun Swaminath, Bruce E Sands, Jean Frederic Colombel, Sunanda Kane, Edward V Loftus, Bo Shen, Corey A Siegel, William J Sandborn, Parambir S Dulai, null null
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. Alimentary pharmacology & therapeutics 52 (4) (2020)
Edward V Loftus, Brian G Feagan, Remo Panaccione, Jean Frederic Colombel, William J Sandborn, Bruce E Sands, Silvio Danese, Geert R A M D'Haens, David T Rubin, Ira Shafran, Andrejus Parfionovas, Raquel Rogers, Richard A Lirio, Severine Vermeire
Long-term safety of vedolizumab for inflammatory bowel disease. Alimentary pharmacology & therapeutics 52 (8) (2020)
Parambir S Dulai, Vipul Jairath, Reena Khanna, Christopher Ma, Kelly P McCarrier, Mona L Martin, Claire E Parker, Joan Morris, Brian G Feagan, William J Sandborn
Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. Alimentary pharmacology & therapeutics 51 (11) (2020)
Bruce E Sands, Alessandro Armuzzi, John K Marshall, James O Lindsay, William J Sandborn, Silvio Danese, Julián Panés, Brian Bressler, Jean Frederic Colombel, Nervin Lawendy, Eric Maller, Haiying Zhang, Gary Chan, Leonardo Salese, Konstantinos Tsilkos, Amy Marren, Chinyu Su
Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply. Alimentary pharmacology & therapeutics 51 (10) (2020)
Edward Yang, Nicola Panaccione, Natalie Whitmire, Parambir S Dulai, Niels Vande Casteele, Siddharth Singh, Brigid S Boland, Angelina Collins, William J Sandborn, Remo Panaccione, Robert Battat
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. Alimentary pharmacology & therapeutics 51 (11) (2020)
Siddharth Singh, Jihoon Kim, Wenhong Zhu, Parambir S Dulai, William J Sandborn, Vipul Jairath
No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Alimentary pharmacology & therapeutics 52 (3) (2020)
Robert Battat, Niels Vande Casteele, Rish K Pai, Zhongya Wang, Guangyong Zou, John W D McDonald, Marjolijn Duijvestein, Jenny Jeyarajah, Claire E Parker, Tanja Van Viegen, Sigrid A Nelson, Brigid S Boland, Siddharth Singh, Parambir S Dulai, Mark A Valasek, Brian G Feagan, Vipul Jairath, William J Sandborn
Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. Alimentary pharmacology & therapeutics 52 (10) (2020)
Edward Yang, Nicola Panaccione, Natalie Whitmire, Parambir S Dulai, Niels Vande Casteele, Siddharth Singh, Brigid S Boland, Angelina Collins, William J Sandborn, Remo Panaccione, Robert Battat
Letter: combination of biologics in inflammatory bowel diseases. Authors' reply. Alimentary pharmacology & therapeutics 52 (3) (2020)
William J Sandborn, Julian Panés, Bruce E Sands, Walter Reinisch, Chinyu Su, Nervin Lawendy, Nana Koram, Haiyun Fan, Thomas V Jones, Irene Modesto, Daniel Quirk, Silvio Danese
Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply. Alimentary pharmacology & therapeutics 51 (11) (2020)
Joseph Meserve, Antonio Facciorusso, Ariela K Holmer, Vito Annese, William J Sandborn, Siddharth Singh
Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases. Alimentary pharmacology & therapeutics 53 (3) (2020)
Remo Panaccione, Silvio Danese, William J Sandborn, Christopher D O'Brien, Yiying Zhou, Hongyan Zhang, Omoniyi J Adedokun, Ilia Tikhonov, Stephan Targan, Maria T Abreu, Tadakazu Hisamatsu, Ellen J Scherl, Rupert W Leong, David S Rowbotham, Ramesh Pulendran Arasaradnam, Bruce E Sands, Colleen Marano
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. Alimentary pharmacology & therapeutics 52 (11-12) (2020)
Parambir S Dulai, Aurelien Amiot, Laurent Peyrin Biroulet, Vipul Jairath, Melanie Serrero, Jerome Filippi, Siddharth Singh, Benjamin Pariente, Edward V Loftus, Xavier Roblin, Sunanda Kane, Anthony Buisson, Corey A Siegel, Yoram Bouhnik, William J Sandborn, Karen Lasch, Maria Rosario, Brian G Feagan, Daniela Bojic, Caroline Trang-Poisson, Bo Shen, Romain Altwegg, Bruce E Sands, Jean Frederic Colombel, Franck Carbonnel, null null
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. Alimentary pharmacology & therapeutics 51 (5) (2019)
Siddharth Singh, Larry W Stitt, Guangyong Zou, Reena Khanna, Parambir S Dulai, William J Sandborn, Brian G Feagan, Vipul Jairath
Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT. Alimentary pharmacology & therapeutics 49 (9) (2019)
Gregor Novak, Toer W Stevens, Tanja Van Viegen, Peter Bossuyt, Borut Štabuc, Jenny Jeyarajah, Guangyong Zou, Ingrid C Gaemers, Trevor D McKee, Fred Fu, Lisa M Shackelton, Reena Khanna, Gijs R van den Brink, William J Sandborn, Brian G Feagan, Rish K Pai, Vipul Jairath, Niels Vande Casteele, Geert D'Haens
Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease. Alimentary pharmacology & therapeutics 49 (11) (2019)
Parambir S Dulai, Siddharth Singh, Vipul Jairath, Christopher Ma, Neeraj Narula, Niels Vande Casteele, Laurent Peyrin Biroulet, Severine Vermeire, Geert D'Haens, Brian G Feagan, William J Sandborn
Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. Alimentary pharmacology & therapeutics 51 (4) (2019)
Siddharth Singh, Parambir S Dulai, Niels Vande Casteele, Robert Battat, Mathurin Fumery, Brigid S Boland, William J Sandborn
Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. Alimentary pharmacology & therapeutics 50 (8) (2019)
Bruce E Sands, Alessandro Armuzzi, John K Marshall, James O Lindsay, William J Sandborn, Silvio Danese, Julian Panes, Brian Bressler, Jean Frederic Colombel, Nervin Lawendy, Eric Maller, Haiying Zhang, Gary Chan, Leonardo Salese, Konstantinos Tsilkos, Amy Marren, Chinyu Su
Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Alimentary pharmacology & therapeutics 51 (2) (2019)
William J Sandborn, Julian Panes, Bruce E Sands, Walter Reinisch, Chinyu Su, Nervin Lawendy, Nana Koram, Haiyun Fan, Thomas V Jones, Irene Modesto, Daniel Quirk, Silvio Danese
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Alimentary pharmacology & therapeutics 50 (10) (2019)
Florian Rieders, D Bettenworth, C Ma, C E Parker, L A Williamson, S A Nelson, G van Assche, Antonio Di Sabatino, Y Bouhnik, Ryan William Stidham, Axel U Dignass, G Rogler, S A Taylor, J Stoker, J Rimola, M E Baker, J G Fletcher, J Panes, William J Sandborn, Brian G Feagan, V Jairath
An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease. Alimentary pharmacology & therapeutics 48 (3) (2018)
Siddharth Singh, M Fumery, William J Sandborn, M H Murad
Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease. Alimentary pharmacology & therapeutics 48 (4) (2018)
William J Sandborn, P Rutgeerts, C Gasink, D Jacobstein, B Zou, J Johanns, B E Sands, Stephen Hanauer, S Targan, Subrata Ghosh, W J S de Villiers, Jean Frederic Colombel, Brian G Feagan
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Alimentary pharmacology & therapeutics 48 (1) (2018)
Christopher Ma, Leonardo Guizzetti, R Panaccione, Richard N Fedorak, Rish K Pai, C E Parker, T M Nguyen, R Khanna, Niels Vande Casteele, Geert R A M D'Haens, William J Sandborn, Brian G Feagan, Vipul Jairath
Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. Alimentary pharmacology & therapeutics 47 (12) (2018)
S Kurnool, N H Nguyen, J Proudfoot, Parambir S Dulai, B S Boland, N Vande Casteele, E Evans, E L Grunvald, A Zarrinpar, William J Sandborn, Siddharth Singh
High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis. Alimentary pharmacology & therapeutics 47 (11) (2018)